Trinity Biotech Plc Stock Net Income
| TRIB Stock | USD 1.10 0.02 1.79% |
Trinity Biotech plc fundamentals help investors to digest information that contributes to Trinity Biotech's financial success or failures. It also enables traders to predict the movement of Trinity Stock. The fundamental analysis module provides a way to measure Trinity Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Trinity Biotech stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -24 M | -22.8 M | |
| Net Income Applicable To Common Shares | 787.5 K | 826.9 K | |
| Net Loss | -36.9 M | -35 M | |
| Net Loss | (3.14) | (2.98) | |
| Net Income Per E B T | 0.65 | 0.68 |
Trinity | Net Income |
Trinity Biotech plc Company Net Income Analysis
Trinity Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Trinity Biotech Net Income | (24.02 M) |
Most of Trinity Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trinity Biotech plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Trinity Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Trinity Biotech is extremely important. It helps to project a fair market value of Trinity Stock properly, considering its historical fundamentals such as Net Income. Since Trinity Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Trinity Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Trinity Biotech's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Trinity Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Trinity Biotech plc reported net income of (24.02 Million). This is 107.04% lower than that of the Health Care Equipment & Supplies sector and 113.87% lower than that of the Health Care industry. The net income for all United States stocks is 104.21% higher than that of the company.
Trinity Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trinity Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trinity Biotech could also be used in its relative valuation, which is a method of valuing Trinity Biotech by comparing valuation metrics of similar companies.Trinity Biotech is currently under evaluation in net income category among its peers.
Trinity Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Trinity Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Trinity Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Trinity Biotech's value.| Shares | Redwood Wealth Management Group Llc | 2024-06-30 | 2 K | Rhumbline Advisers | 2024-06-30 | 372 | Jones Financial Companies Lllp | 2024-06-30 | 308 | Bank Of America Corp | 2024-06-30 | 240 | Atlantic Trust Group, Llc | 2024-06-30 | 222 | Simplex Trading, Llc | 2024-06-30 | 42.0 | Atwood & Palmer Inc | 2024-09-30 | 20.0 | Stonehill Capital Management Llc | 2024-06-30 | 0.0 | Cgc Financial Services Llc | 2024-06-30 | 0.0 | Perceptive Advisors Llc | 2024-09-30 | 1.8 M | Hunter Associates Inc. | 2024-09-30 | 359.8 K |
Trinity Fundamentals
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.0964 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 120.92 M | ||||
| Shares Outstanding | 27.32 M | ||||
| Shares Owned By Insiders | 19.68 % | ||||
| Shares Owned By Institutions | 23.90 % | ||||
| Number Of Shares Shorted | 76.94 K | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.52 X | ||||
| Revenue | 56.83 M | ||||
| Gross Profit | 38.08 M | ||||
| EBITDA | (24.1 M) | ||||
| Net Income | (24.02 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 67.43 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (3.12) X | ||||
| Cash Flow From Operations | (11.56 M) | ||||
| Short Ratio | 0.43 X | ||||
| Earnings Per Share | (2.25) X | ||||
| Price To Earnings To Growth | 1.30 X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 380 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 30.46 M | ||||
| Total Asset | 59.44 M | ||||
| Retained Earnings | (48.64 M) | ||||
| Working Capital | 24.01 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
| Net Asset | 59.44 M |
About Trinity Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Trinity Biotech plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trinity Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trinity Biotech plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out Trinity Biotech Piotroski F Score and Trinity Biotech Altman Z Score analysis. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share 6.968 | Quarterly Revenue Growth 0.14 | Return On Assets (0.1) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.